Home › NDC Lookup › RxCUI directory › RxCUI 2693458

23 ML hyaluronidase-ocsq 1000 UNT/ML / ocrelizumab-ocsq 40 MG/ML Injection — RxCUI 2693458

RxNorm drug concept · Semantic clinical drug
RxCUI 2693458 Semantic clinical drug · SCD ● Current RxNorm concept 1 FDA product 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2693458
Official name23 ML hyaluronidase-ocsq 1000 UNT/ML / ocrelizumab-ocsq 40 MG/ML Injection
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asocrelizumab-hyaluronidase-ocsq 920 MG / 23,000 UNT per 23 ML Injection; ocrelizumab-ocsq 920 MG / hyaluronidase-ocsq 23,000 UNT in 23 ML Injection; ocrelizumab-ocsq 920 MG / hyaluronidase-ocsq 23,000 UNT per 23 ML Injection
FDA products mapped1
Package NDCs mapped2
Reported Medicaid activity (SDUD)15 prescriptions · 1 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Ocrelizumab Injection: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • No, it actually covers several types of MS. For adults, Ocrevus is approved for relapsing forms of MS — which includes clinically isolated syndrome, relapsing-remitting MS, and act...
  • What exactly is Ocrevus used for — is it only for one type of MS?
  • Ocrevus is given through an IV drip at a clinic or infusion center, not at home. Before the infusion starts, you'll be given a steroid, an antihistamine, and possibly a fever-reduc...
  • What happens during an infusion — what should I expect?
📖 Read our full Ocrelizumab Injection guide →

🕸️ Concept Web — How 23 ML hyaluronidase-ocsq 1000 UNT/ML / ocrelizum... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 23 ML hyaluronidase-ocsq 1000 UNT/ML / ocrelizumab-ocsq 40 MG/ML Injection RxCUI 2693458

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 5

    The active substance itself — no strength, form, or brand attached yet.

    • Hyaluronidase 5464
    • Ocrelizumab 1876366
    • Hyaluronidase / ocrelizumab 2693453
    • Hyaluronidase-ocsq 2693451
    • Ocrelizumab-ocsq 2693449
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Ocrevus Zunovo 2693460
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Hyaluronidase / ocrelizumab Injection 2693455
    • Hyaluronidase-ocsq / ocrelizumab-ocsq Injection 2693457
    • Hyaluronidase / ocrelizumab Injectable Product 2693454
    • Hyaluronidase-ocsq / ocrelizumab-ocsq Injectable Product 2693456
    • Hyaluronidase / ocrelizumab Injection [Ocrevus Zunovo] 2693463
    • Hyaluronidase-ocsq / ocrelizumab-ocsq Injection [Ocrevus Zunovo] 2693464
    • Ocrevus Zunovo Injectable Product 2693462
    • Injection 1649574
    • +1 more in this family
  4. Clinical & branded drugs 4

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 18 of 19 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Hyaluronidase-ocsq 1000 UNT/ML SCDC · 2693452
  • Ocrelizumab-ocsq 40 MG/ML SCDC · 2693450
  • Hyaluronidase / ocrelizumab Injection SCDF · 2693455
  • Hyaluronidase-ocsq / ocrelizumab-ocsq Injection SCDFP · 2693457
  • Hyaluronidase / ocrelizumab Injectable Product SCDG · 2693454
  • Hyaluronidase-ocsq / ocrelizumab-ocsq Injectable Product SCDGP · 2693456

Brand-Name Concepts

📦 FDA Products & Package NDCs

1 product · 2 package NDCs
2 package NDCs map to RxCUI 2693458 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
50242-0554-01 1 VIAL, SINGLE-USE in 1 CARTON (50242-554-01) / 23 mL in 1... Ocrevus Zunovo Genentech, Inc. 2024-09-13
50242-0554-86 1 VIAL, SINGLE-USE in 1 CARTON (50242-554-86) / 23 mL in 1... Ocrevus Zunovo Genentech, Inc. 2024-09-13
Observed labelers: Genentech, Inc. (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🧾 Billing Codes (HCPCS)

Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.
CodeDescriptorMapped packagesSources
J2351 Inj ocrelizumab 1mg hya-ocsq 1 CMS
⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.